Literature DB >> 12668911

Predicting coronary risk in the general population--is it necessary to measure high-density lipoprotein cholesterol?

Sarah Wilson1, Atholl Johnston, John Robson, Neil R Poulter, David J Collier, Gene S Feder, Mark J Caulfield.   

Abstract

BACKGROUND: The Joint British Societies Coronary Risk Prediction Charts recommend the use of a high-density lipoprotein cholesterol value of 1 mmol/l where actual values have not been measured. It is important to quantify the impact of this advice if risk assessments are to be sufficiently accurate to guide treatment decisions.
DESIGN: The risks of 5005 individuals from the Health Survey for England 1998 were calculated using the Joint British Societies charts. Each individual's risk was recalculated assuming a high-density lipoprotein cholesterol value of 1 mmol/l. These risk estimates were compared with those derived from the Framingham equation.
METHODS: Using the Framingham equation as the gold standard, the positive and negative predictive values, sensitivity and specificity with 95% confidence intervals of the Joint British charts with actual and estimated high-density lipoprotein cholesterol values were calculated.
RESULTS: At the 30% 10-year coronary heart disease risk threshold using measured high-density lipoprotein cholesterol values, the charts had a sensitivity of 83% and specificity of 99%. Using an estimated high-density lipoprotein cholesterol value of 1 mmol/l reduced the sensitivity to 58% with a specificity of 98%.
CONCLUSIONS: In the presence of measured high-density lipoprotein cholesterol values there was good agreement between the Framingham equation and the Joint British Societies charts. The use of a fixed high-density lipoprotein cholesterol value of 1 mmol/l introduced important and significant errors into the risk assessment. This study reinforces the need to measure both total and high-density lipoprotein cholesterol when assessing coronary risk.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668911     DOI: 10.1097/01.hjr.0000060844.48106.ff

Source DB:  PubMed          Journal:  J Cardiovasc Risk        ISSN: 1350-6277


  3 in total

1.  Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix.

Authors:  Matthew R Smith; Laurence Klotz; Egbert van der Meulen; Enrico Colli; László B Tankó
Journal:  J Urol       Date:  2011-09-25       Impact factor: 7.450

Review 2.  Exercise, vascular wall and cardiovascular diseases: an update (part 2).

Authors:  Lai Ming Yung; Ismail Laher; Xiaoqiang Yao; Zhen Yu Chen; Yu Huang; Fung Ping Leung
Journal:  Sports Med       Date:  2009       Impact factor: 11.136

3.  Comparison of methods to identify individuals at increased risk of coronary disease from the general population.

Authors:  S Wilson; A Johnston; J Robson; N Poulter; D Collier; G Feder; M J Caulfield
Journal:  BMJ       Date:  2003-06-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.